CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production

Keai Sinn Tan, Dongfang Wang, Ziqiang Lu, Yihan Zhang, Sixu Li, Yue Lin, Wen TanInternational Journal of Molecular Sciences 2021 · DOI

TL;DR

This study identifies 2',3'-cyclic nucleotide-3'-phosphodiesterase (CNPase) as a potential therapeutic target for heart failure. By enhancing mitochondrial energy production, CNPase appears to protect the heart from hypertrophy and dysfunction, offering a novel approach to combat this widespread disease.

What Problem Does This Paper Address?

Heart failure, a leading cause of death worldwide, is characterized by the heart's inability to pump blood effectively. A key underlying issue is insufficient mitochondrial energy production, which fails to meet the heart's high energy demands. While the role of mitochondria in heart failure is recognized, the specific molecular players regulating their energy output and how they contribute to pathological conditions like cardiac hypertrophy remain incompletely understood. This paper aims to elucidate the role of CNPase, an enzyme previously linked to mitochondrial integrity, in the context of heart failure and explore its therapeutic potential.

Methods

The researchers employed a multi-pronged approach:

  • Zebrafish Models: They established heart failure models in zebrafish using two distinct methods:
  • Antisense Morpholino Oligonucleotides (MO): This technique was used to "knock down" CNPase expression, effectively reducing its levels.
  • CRISPR-Cas9 Gene Editing: This allowed for the precise knockout of the CNPase gene, creating a more definitive genetic model.
  • Rat Model of Cardiac Hypertrophy: To translate findings to a mammalian system, they induced cardiac hypertrophy in rats using transverse abdominal aorta constriction (TAAC).
  • AAV9-Mediated Gene Delivery: Adeno-associated virus serotype 9 (AAV9) was used to deliver CNPase gene therapy directly into the rat myocardium. AAV9 is known for its efficiency in targeting cardiac tissue.
  • Echocardiography: This non-invasive imaging technique was used to assess cardiac function (e.g., ejection fraction, fractional shortening, cardiac output) in both zebrafish and rats.
  • Transmission Electron Microscopy (TEM): This high-resolution microscopy technique was used to examine the ultrastructure of mitochondria in cardiac tissue.
  • Seahorse Cellular Energy Analyzer: This instrument was used to measure mitochondrial respiration and ATP production in cell cultures.
  • In Silico Simulation (Molecular Docking, Molecular Dynamics): Computational methods were used to predict and analyze the binding interactions of CNPase with its substrates.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • CNPase is Crucial for Heart Function: Silencing CNPase in zebrafish larvae led to severe heart failure phenotypes, including pericardial edema, enlarged ventricles, bradycardia, and reduced cardiac output, strongly suggesting its essential role in maintaining cardiac health.
  • CNPase Protects Against Hypertrophy: In a rat model of pressure overload-induced cardiac hypertrophy, AAV9-mediated delivery of CNPase significantly attenuated the hypertrophic response, reducing heart weight-to-body weight ratios and cardiomyocyte size.
  • Mitochondrial Integrity is Key: CNPase appears to protect mitochondrial ultrastructure, preserving cristae integrity and preventing the formation of abnormal membrane whorls, which are hallmarks of mitochondrial damage in failing hearts.
  • CNPase Enhances Mitochondrial Respiration: In cell culture models, CNPase overexpression improved mitochondrial respiration and ATP production, particularly under conditions of stress (AngII-induced hypertrophy). This directly links CNPase activity to improved energy supply.
  • Specific Substrate Preference: In silico simulations confirmed that CNPase preferentially binds to 2',3'-cyclic nucleotides over the more common 3',5'-cyclic nucleotides, highlighting its specific enzymatic role. This specificity is crucial for understanding its therapeutic mechanism.
  • Potential Anti-inflammatory Role: The observation of reduced pericardial edema in CNPase-deficient zebrafish, coupled with literature suggesting CNPase's role in regulating inflammatory cytokines, hints at a potential anti-inflammatory contribution to its cardioprotective effects.

Key Results

  • Zebrafish Knockdown: Over 85% of cnpase-knocked-down zebrafish larvae died within three days post-fertilization, exhibiting significant cardiac dysfunction.
  • Rat Model Improvement: In TAAC rats treated with AAV9-CNPase, cardiac output, ejection fraction, and fractional shortening were significantly improved compared to control groups.
  • Reduced Hypertrophy and Fibrosis: CNPase delivery in TAAC rats led to a reduction in heart weight-to-body weight ratio, heart weight-to-tibia length ratio, cardiomyocyte cross-sectional area, and interstitial fibrosis.
  • Enhanced Mitochondrial Function: In H9c2 cells, CNPase overexpression increased basal, maximal, and ATP-linked oxygen consumption rates, indicating improved mitochondrial respiration.

Limitations and Future Work

The authors acknowledge several limitations and suggest future research directions:

  • Rescue Experiment: A crucial next step is to perform a rescue experiment where reintroducing CNPase into cnpase-deficient models can reverse the observed pathological phenotypes. This would further solidify the causal link.
  • In Vivo Energy Expenditure and Biomarkers: The study would benefit from detailed in vivo measurements of energy expenditure and metabolic biomarkers to fully characterize the effects of CNPase therapy.
  • Molecular Role and Mechanism: While the study provides mechanistic insights, further investigation is needed to fully elucidate the precise molecular mechanisms by which CNPase influences mitochondrial function and cardiac remodeling.
  • CNPase and Inflammation: The potential link between CNPase, 2',3'-cGMP, and inflammatory pathways (e.g., TLR7 activation) warrants further exploration to understand how CNPase might modulate inflammation in heart failure.
  • Therapeutic Window and Dosage: Determining the optimal therapeutic window and dosage for CNPase-based therapies in larger animal models and eventually humans is essential.

Summary updated

Abstract

Heart failure is the end-stage of all cardiovascular diseases with a ~25% 5-year survival rate, and insufficient mitochondrial energy production to meet myocardial demand is the hallmark of heart failure. Mitochondrial components involved in the regulation of ATP production remain to be fully elucidated. Recently, roles of 2',3'-cyclic nucleotide-3'-phosphodiesterase (CNPase) in the pathophysiological processes of heart diseases have emerged, implicated by evidence that mitochondrial CNPase proteins are associated with mitochondrial integrity under metabolic stress. In this study, a zebrafish heart failure model was established, by employing antisense morpholino oligonucleotides and the CRISPR-Cas9 gene-editing system, which recapitulates heart failure phenotypes including heart dysfunction, pericardial edema, ventricular enlargement, bradycardia, and premature death. The translational implications of CNPase in the pathophysiological process of heart failure were tested in a pressure overload-induced heart hypertrophy model, which was carried out in rats through transverse abdominal aorta constriction (TAAC). AAV9-mediated myocardial delivery of CNPase mitigated the hypertrophic response through the specific hydrolysis of 2'-3'-cyclic nucleotides, supported by the decrease of cardiac hypertrophy and fibrosis, the integrity of mitochondrial ultrastructure, and indicators of heart contractility in the AAV9-TAAC group. Finally, the biometrics of a mitochondrial respiration assay carried out on a Seahorse cellular energy analyzer demonstrated that CNPase protects mitochondrial respiration and ATP production from AngII-induced metabolic stress. In summary, this study provides mechanistic insights into CNPase-2',3'-cyclic nucleotide metabolism that protects the heart from energy starvation and suggests novel therapeutic approaches to treat heart failure by targeting CNPase activity.
BibTeX
@article{tan2021cnpase,
  author = {Keai Sinn Tan and Dongfang Wang and Ziqiang Lu and Yihan Zhang and Sixu Li and Yue Lin and Wen Tan},
  title = {{CNPase, a 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, as a Therapeutic Target to Attenuate Cardiac Hypertrophy by Enhancing Mitochondrial Energy Production}},
  journal = {International Journal of Molecular Sciences},
  year = {2021},
  doi = {10.3390/ijms221910806},
}
Figure